Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (STABL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.219x
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has a cash flow conversion efficiency ratio of -0.219x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.85 Million) by net assets (Skr8.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Stayble Therapeutics AB - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Stayble Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Stayble Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stayble Therapeutics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
0.089x |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
0.988x |
|
Silicon Gaming Inc
PINK:SGIC
|
0.033x |
|
Exro Technologies Inc
OTCQB:EXROF
|
0.254x |
|
Av Gad Holdings Ltd
TA:AVGD
|
-0.357x |
|
HUA YIN INTL HLDGS LTD
F:CL7
|
N/A |
|
ZWACK UNICUM
MU:ZWC1
|
0.131x |
|
BBS-Bioactive Bone Substitutes Oyj
HE:BONEH
|
-0.416x |
Annual Cash Flow Conversion Efficiency for Stayble Therapeutics AB (2016–2024)
The table below shows the annual cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr6.87 Million | Skr-14.67 Million | -2.134x | -49.66% |
| 2023-12-31 | Skr16.51 Million | Skr-23.54 Million | -1.426x | +12.45% |
| 2022-12-31 | Skr15.28 Million | Skr-24.89 Million | -1.628x | -572.99% |
| 2021-12-31 | Skr39.81 Million | Skr-9.63 Million | -0.242x | +84.31% |
| 2020-12-31 | Skr15.55 Million | Skr-23.98 Million | -1.542x | -57.46% |
| 2019-12-31 | Skr-295.44K | Skr289.39K | -0.980x | -28.49% |
| 2018-12-31 | Skr7.11 Million | Skr-5.42 Million | -0.762x | -140.22% |
| 2017-12-31 | Skr8.25 Million | Skr-2.62 Million | -0.317x | -152.05% |
| 2016-12-31 | Skr11.06 Million | Skr-1.39 Million | -0.126x | -- |